GlassScriptPhysician profile
Dannyel Robinson
NPI 1760046452
$507.79
in general payments reported to CMS, 2019-2025
15 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $487 · 2022: $20.75.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $191.69 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $43.18 | 2021 | |
| Nestle Healthcare Nutrition INC. | $38.29 | 2021 | |
| Eisai INC. | $31.90 | 2021 | |
| Novo Nordisk INC | $30.31 | 2021 | |
| Alnylam Pharmaceuticals INC. | $21.83 | 2021 | |
| Radius Health, INC. | $21.40 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $20.75 | 2022 | |
| Esperion Therapeutics, INC. | $18.52 | 2021 | |
| Lilly USA, LLC | $16.21 | 2021 | |
| Daiichi Sankyo INC. | $15.80 | 2021 | |
| Amarin Pharma, INC. | $15.75 | 2021 | |
| Gilead Sciences, INC. | $15.65 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $14.48 | 2021 | |
| Ironwood Pharmaceuticals, INC | $12.03 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dannyel Robinson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.